Cardiometabolic Diseases Research

Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes. Our current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic Steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity. Around 300 scientists work in our fully integrated drug discovery centre of excellence for Cardiometabolic research at sites in Biberach, Germany and Ridgefield, CT, USA.

 

Our Discovery Research focus is on:
 

  • Type 2 diabetes
  • Micro- and macrovascular complications of diabetes – e.g. diabetic retinopathy, diabetic nephropathy, chronic kidney diseases, CV outcomes
  • Liver diseases – e.g. NASH
  • Obesity